{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T22:15:54Z","timestamp":1767910554689,"version":"3.49.0"},"reference-count":64,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T00:00:00Z","timestamp":1717113600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Daewoong Pharmaceutical Co., Ltd., Seoul, Korea","award":["DWP14012"],"award-info":[{"award-number":["DWP14012"]}]}],"content-domain":{"domain":["www.mdpi.com"],"crossmark-restriction":true},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Fexuprazan (Fexuclue\u00ae; Daewoong Pharmaceutical Co., Ltd., Seoul, Korea) is a novel potassium-competitive acid blocker (P-CAB). This multi-center, randomized, double-blind, active-controlled, parallel-group, therapeutic confirmatory, phase III study was conducted to assess its efficacy and safety compared with esomeprazole (Nexium\u00ae; AstraZeneca, Gothenburg, M\u00f6lndal, Sweden) in Korean patients with erosive esophagitis (EE). Methods: This study evaluated patients diagnosed with EE at a total of 25 institutions in Korea between 13 December 2018 and 7 August 2019. After voluntarily submitting a written informed consent form, the patients were evaluated using a screening test and then randomized to either of the two treatment arms. The proportion of the patients who achieved the complete recovery of mucosal breaks at 4 and 8 weeks, the proportion of those who achieved the complete recovery of heartburn at 3 and 7 days and 8 weeks, and changes in the GERD\u2013Health-Related Quality of Life Questionnaire (GERD-HRQL) scores at 4 and 8 weeks from baseline served as efficacy outcome measures. The incidence of treatment-emergent adverse events (TEAEs) and adverse drug reactions (ADRs) and the serum gastrin levels served as safety outcome measures. Results: The study population comprised a total of 231 patients (n = 231) with EE, including 152 men (65.80%) and 79 women (34.20%); their mean age was 54.37 \u00b1 12.66 years old. There were no significant differences in the efficacy and safety outcome measures between the two treatment arms (p &gt; 0.05). Conclusions: It can be concluded that the efficacy and safety of Fexuclue\u00ae are not inferior to those of esomeprazole in Korean patients with EE.<\/jats:p>","DOI":"10.3390\/jcm13113262","type":"journal-article","created":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T11:43:48Z","timestamp":1717155828000},"page":"3262","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["RETRACTED: A Phase III Head-to-Head Study to Compare the Efficacy and Safety of Fexuprazan and Esomeprazole in Treating Patients with Erosive Esophagitis"],"prefix":"10.3390","volume":"13","author":[{"given":"Yuchul","family":"Jeong","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Chungna Good Hospital, Incheon 22738, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beom","family":"Lee","sequence":"additional","affiliation":[{"name":"St. Mary\u2019s Best ENT Clinic, Seoul 08849, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1681-7029","authenticated-orcid":false,"given":"Se-Hyeon","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Companion Animal Industry, College of Health Science, Honam University, Gwangju 62399, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,5,31]]},"reference":[{"key":"ref_1","first-page":"214","article-title":"Gastroesophageal Reflux Disease (GERD)","volume":"115","author":"Clarrett","year":"2018","journal-title":"Mo. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3748\/wjg.v5.i1.4","article-title":"Gastroesophageal Reflux Disease Is Uncommon in Asia: Evidence and Possible Explanations","volume":"5","author":"Ho","year":"1999","journal-title":"World J. Gastroenterol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"726","DOI":"10.5009\/gnl15406","article-title":"Antireflux Surgery in Korea: A Nationwide Study from 2011 to 2014","volume":"10","author":"Lee","year":"2016","journal-title":"Gut Liver"},{"key":"ref_4","first-page":"241","article-title":"Pathophysiology of Gastro-Oesophageal Reflux Disease","volume":"26","author":"Giorgi","year":"2006","journal-title":"Acta Otorhinolaryngol. Ital."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.3346\/jkms.2010.25.9.1318","article-title":"Differences in Clinical Characteristics Between Patients with Non-Erosive Reflux Disease and Erosive Esophagitis in Korea","volume":"25","author":"Ha","year":"2010","journal-title":"J. Korean Med. Sci."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Deppe, H., M\u00fccke, T., Wagenpfeil, S., Kesting, M., Rozej, A., Bajbouj, M., and Sculean, A. (2015). Erosive esophageal reflux vs. non erosive esophageal reflux: Oral findings in 71 patients. BMC Oral Health, 15.","DOI":"10.1186\/s12903-015-0069-8"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2147\/JMDH.S54324","article-title":"Gastrointestinal Ulcers, Role of Aspirin, and Clinical Outcomes: Pathobiology, Diagnosis, and Treatment","volume":"7","author":"Cryer","year":"2014","journal-title":"J. Multidiscip. Healthc."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1007\/s00535-015-1038-3","article-title":"Management of Low-Dose Aspirin and Clopidogrel in Clinical Practice: A Gastrointestinal Perspective","volume":"50","author":"Lanas","year":"2015","journal-title":"J. Gastroenterol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1007\/s11894-008-0098-4","article-title":"Pharmacology of Proton Pump Inhibitors","volume":"10","author":"Shin","year":"2008","journal-title":"Curr. Gastroenterol. Rep."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1586\/ecp.09.33","article-title":"Long Lasting Inhibitors of the Gastric H,K-ATPase","volume":"2","author":"Shin","year":"2009","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/MED.0000000000000448","article-title":"Gastrointestinal hormones and regulation of gastric emptying","volume":"26","author":"Camilleri","year":"2019","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/01.md.0000236956.74128.76","article-title":"Serum gastrin in Zollinger-Ellison syndrome: I. Prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2229 cases from the literature","volume":"85","author":"Berna","year":"2006","journal-title":"Medicine"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1080\/17425255.2018.1461835","article-title":"Proton Pump Inhibitors: From CYP2C19 Pharmacogenetics to Precision Medicine","volume":"14","author":"Rouby","year":"2018","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1365-2036.2004.02161.x","article-title":"Review Article: Relationship Between the Metabolism and Efficacy of Proton Pump Inhibitors\u2013Focus on Rabeprazole","volume":"20","author":"Horn","year":"2004","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"437","DOI":"10.2165\/11599320-000000000-00000","article-title":"Prescribing proton pump inhibitors: Is it time to pause and rethink?","volume":"72","author":"Vakil","year":"2012","journal-title":"Drugs"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"5527","DOI":"10.1038\/s41598-017-05552-1","article-title":"Proton Pump Inhibitors and the Risk for Fracture at Specific Sites: Data Mining of the FDA Adverse Event Reporting System","volume":"7","author":"Wang","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"63","DOI":"10.4292\/wjgpt.v9.i7.63","article-title":"Potassium-competitive Acid Blockers\u2014Are They the Next Generation of Proton Pump Inhibitors?","volume":"9","author":"Rawla","year":"2018","journal-title":"World J. Gastrointest. Pharmacol. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/apt.13461","article-title":"Randomised Clinical Trial: Vonoprazan, a Novel Potassium-Competitive Acid Blocker, vs. Lansoprazole for the Healing of Erosive Oesophagitis","volume":"43","author":"Ashida","year":"2016","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.3748\/wjg.v24.i14.1550","article-title":"Maintenance for Healed Erosive Esophagitis: Phase III Comparison of Vonoprazan with Lansoprazole","volume":"24","author":"Ashida","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1111\/apt.15185","article-title":"Randomised Phase 3 Trial: Tegoprazan, a Novel Potassium-Competitive Acid Blocker, vs. Esomeprazole in Patients with Erosive Oesophagitis","volume":"49","author":"Lee","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1177\/1756283X17705329","article-title":"A randomized, double-blind study to evaluate the acid-inhibitory effect of vonoprazan (20 mg and 40 mg) in patients with proton-pump inhibitor-resistant erosive esophagitis","volume":"10","author":"Iwakiri","year":"2017","journal-title":"Therap. Adv. Gastroenterol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.kjms.2017.07.004","article-title":"Vonoprazan treatment improves gastrointestinal symptoms in patients with gastroesophageal reflux disease","volume":"33","author":"Shinozaki","year":"2017","journal-title":"Kaohsiung J. Med. Sci."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1038\/ctg.2015.39","article-title":"Potassium-competitive acid blockers (PCABs): Are they finally ready for prime time in acid-related disease","volume":"6","author":"Hunt","year":"2015","journal-title":"Clin. Transl. Gastroenterol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1136\/gutjnl-2015-311304","article-title":"Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: A phase III, randomised, double-blind study","volume":"65","author":"Murakami","year":"2016","journal-title":"Gut"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.curtheres.2016.12.001","article-title":"Evaluation of the efficacy and safety of vonoprazan in patients with nonerosive gastroesophageal reflux disease: A phase iii, randomized, double-blind, placebo-controlled, multicenter study","volume":"81\u201382","author":"Kinoshita","year":"2016","journal-title":"Curr. Ther. Res. Clin. Exp."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1046\/j.1365-2036.2000.00856.x","article-title":"Esomeprazole Improves Healing and Symptom Resolution as Compared With Omeprazole in Reflux Oesophagitis Patients: A Randomized Controlled Trial. The Esomeprazole Study Investigators","volume":"14","author":"Kahrilas","year":"2000","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/apt.14864","article-title":"Editorial: Control of Acid Secretion","volume":"48","author":"Sachs","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1111\/apt.15480","article-title":"Editorial: Potassium-Competitive Acid Blockers for Acid-Related Diseases-Tegoprazan, a New Kid on the Block","volume":"50","author":"Scarpignato","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11894-020-0753-y","article-title":"Novel Therapies for Gastroesophageal Reflux Disease: Beyond Proton Pump Inhibitors","volume":"22","author":"Shibli","year":"2020","journal-title":"Curr. Gastroenterol. Rep."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1007\/s11938-018-0206-y","article-title":"Potent Acid Suppression with PPIs and P-CABs: What\u2019s New?","volume":"16","author":"Hunt","year":"2018","journal-title":"Curr. Treat. Options Gastroenterol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"334","DOI":"10.5056\/jnm18029","article-title":"Potent Potassium-competitive Acid Blockers: A New Era for the Treatment of Acid-related Diseases","volume":"24","author":"Oshima","year":"2018","journal-title":"J. Neurogastroenterol. Motil."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e12640","DOI":"10.1111\/hel.12640","article-title":"Review: Treatment of Helicobacter Pylori Infection 2019","volume":"24","author":"Liou","year":"2019","journal-title":"Helicobacter"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"6","DOI":"10.5056\/jnm18139","article-title":"Role of Acid Suppression in Acid-related Diseases: Proton Pump Inhibitor and Potassium-competitive Acid Blocker","volume":"25","author":"Mori","year":"2019","journal-title":"J. Neurogastroenterol. Motil."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/apt.14818","article-title":"Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of DWP14012, a Novel Potassium-Competitive Acid Blocker, in Healthy Male Subjects","volume":"48","author":"Sunwoo","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/j.1365-2036.2005.02368.x","article-title":"A Randomized Comparative Study of Esomeprazole 40 Mg Versus Pantoprazole 40 Mg for Healing Erosive Oesophagitis: The EXPO Study","volume":"21","author":"Labenz","year":"2005","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/j.1572-0241.2001.03600.x","article-title":"Efficacy and Safety of Esomeprazole Compared with Omeprazole in GERD Patients with Erosive Esophagitis: A Randomized Controlled Trial","volume":"96","author":"Richter","year":"2001","journal-title":"Am. J. Gastroenterol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/j.1365-2036.2009.03933.x","article-title":"Clinical Trials: Healing of Erosive Oesophagitis with Dexlansoprazole MR, a Proton Pump Inhibitor with a Novel Dual Delayed-Release Formulation\u2013Results from Two Randomized Controlled Studies","volume":"29","author":"Sharma","year":"2009","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_38","first-page":"234","article-title":"Efficacy of Esomeprazole Compared With Omeprazole in Reflux Esophagitis Patients\u2014A Phase III, Multicenter, Randomized, Double-Blind, Parallel-Group Trial-","volume":"110","author":"Kinoshita","year":"2013","journal-title":"Nihon Shokakibyo Gakkai Zasshi"},{"key":"ref_39","first-page":"653","article-title":"A review of esomeprazole in the treatment of gastroesophageal reflux disease (GERD)","volume":"3","author":"Kalaitzakis","year":"2007","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1111\/j.1742-1241.2008.01923.x","article-title":"The effectiveness of esomeprazole 40 mg in patients with persistent symptoms of gastro-oesophageal reflux disease following treatment with a full dose proton pump inhibitor","volume":"62","author":"Jones","year":"2008","journal-title":"Int. J. Clin. Pract."},{"key":"ref_41","first-page":"217","article-title":"Quality of life scale for gastroesophageal reflux disease","volume":"183","author":"Velanovich","year":"1996","journal-title":"J. Am. Coll. Surg."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"7","DOI":"10.5009\/gnl16615","article-title":"Current Trends in the Management of Gastroesophageal Reflux Disease","volume":"12","author":"Sandhu","year":"2018","journal-title":"Gut Liver"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1007\/s10620-014-3104-8","article-title":"Gastric Acid-Dependent Diseases: A Twentieth-Century Revolution","volume":"59","author":"Sachs","year":"2014","journal-title":"Dig. Dis. Sci."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3298","DOI":"10.1007\/s10620-017-4830-5","article-title":"Recent Advances in the Pharmacological Management of Gastroesophageal Reflux Disease","volume":"62","author":"Kung","year":"2017","journal-title":"Dig. Dis. Sci."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s10620-018-5365-0","article-title":"Short-Term Symptomatic Relief in Gastroesophageal Reflux Disease: A Comparative Study of Esomeprazole and Vonoprazan","volume":"64","author":"Sakurai","year":"2019","journal-title":"Dig. Dis. Sci."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/apt.15062","article-title":"Randomised Clinical Trial: Vonoprazan Versus Lansoprazole for the Initial Relief of Heartburn in Patients with Erosive Oesophagitis","volume":"49","author":"Oshima","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1136\/gutjnl-2019-318365","article-title":"Phase III, Randomised, Double-Blind, Multicentre Study to Evaluate the Efficacy and Safety of Vonoprazan Compared with Lansoprazole in Asian Patients With Erosive Oesophagitis","volume":"69","author":"Xiao","year":"2020","journal-title":"Gut"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1159\/000080308","article-title":"Review of the quality of life and burden of illness in gastroesophageal reflux disease","volume":"22","author":"Wiklund","year":"2004","journal-title":"Dig. Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1111\/j.1365-2036.2008.03671.x","article-title":"Relationship between symptom load of gastrooesophageal reflux disease and health-related quality of life, work productivity, resource utilization and concomitant diseases: Survey of a US cohort","volume":"27","author":"Wahlqvist","year":"2008","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"4614","DOI":"10.3748\/wjg.v17.i41.4614","article-title":"Comparison of presentation and impact on quality of life of gastroesophageal reflux disease between young and old adults in a Chinese population","volume":"17","author":"Lee","year":"2011","journal-title":"World J. Gastroenterol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"5090","DOI":"10.3748\/wjg.v18.i36.5090","article-title":"Impact of body mass index and gender on quality of life in patients with gastroesophageal reflux disease","volume":"18","author":"Lee","year":"2012","journal-title":"World J. Gastroenterol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"iv35","DOI":"10.1136\/gut.2003.034314","article-title":"Quality of Life Assessment in Gastro-Oesophageal Reflux Disease","volume":"53","author":"Irvine","year":"2004","journal-title":"Gut"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1111\/j.1572-0241.2003.07531.x","article-title":"Nighttime heartburn is an under-appreciated clinical problem that impacts sleep and daytime function: The results of a gallup survey conducted on behalf of the american gastroenterological association","volume":"98","author":"Shaker","year":"2003","journal-title":"Am. J. Gastroenterol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/archinte.161.1.45","article-title":"The impact of nocturnal symptoms associated with gastroesophageal reflux disease on health-related quality of life","volume":"161","author":"Farup","year":"2001","journal-title":"Arch. Intern. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/ajg.2012.19","article-title":"Efficacy of twice-daily rabeprazole for reflux esophagitis patients refractory to standard once-daily administration of PPI: The Japan-based TWICE study","volume":"107","author":"Kinoshita","year":"2012","journal-title":"Am. J. Gastroenterol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1007\/s10620-010-1209-2","article-title":"Patient and physician satisfaction with proton pump inhibitors (PPIs): Are there opportunities for improvement?","volume":"55","author":"Chey","year":"2010","journal-title":"Dig. Dis. Sci."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/0016-5085(90)90946-X","article-title":"Effect of long-term treatment with omeprazole on serum gastrin and serum group A and C pepsinogens in patients with reflux esophagitis","volume":"99","author":"Jansen","year":"1990","journal-title":"Gastroenterology"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s40262-015-0326-7","article-title":"The first-in-class potassium-competitive acid blocker, vonoprazan fumarate: Pharmacokinetic and pharmacodynamic considerations","volume":"55","author":"Echizen","year":"2016","journal-title":"Clin. Pharmacokinet."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1159\/000484217","article-title":"Does the novel potassiumcompetitive acid blocker vonoprazan cause more hypergastrinemia than conventional proton pump inhibitors? A multicenter prospective crosssectional study","volume":"97","author":"Kojima","year":"2018","journal-title":"Digestion"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1055\/s-0035-1556063","article-title":"Comorbidities and Chronic Obstructive Pulmonary Disease: Prevalence, Influence on Outcomes, and Management","volume":"36","author":"Putcha","year":"2015","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.2147\/COPD.S77562","article-title":"Gastroesophageal Reflux Disease in COPD: Links and Risks","volume":"10","author":"Lee","year":"2015","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1365-2036.2007.03561.x","article-title":"The prevalence of and risk factors for erosive oesophagitis and non-erosive reflux disease: A nationwide multicentre prospective study in Korea","volume":"27","author":"Kim","year":"2008","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Yamamichi, N., Mochizuki, S., Asada-Hirayama, I., Mikami-Matsuda, R., Shimamoto, T., Konno-Shimizu, M., Takahashi, Y., Takeuchi, C., Niimi, K., and Ono, S. (2012). Lifestyle factors affecting gastroesophageal reflux disease symptoms: A cross-sectional study of healthy 19864 adults using FSSG scores. BMC Med., 10.","DOI":"10.1186\/1741-7015-10-45"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/jgh.12103","article-title":"Acid burn or cytokine sizzle in the pathogenesis of heartburn?","volume":"28","author":"Huo","year":"2013","journal-title":"J. Gastroenterol. Hepatol."}],"updated-by":[{"DOI":"10.3390\/jcm13216388","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T00:00:00Z","timestamp":1729814400000},"record-id":"58357"},{"DOI":"10.3390\/jcm13216388","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T00:00:00Z","timestamp":1717113600000}}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/11\/3262\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,3]],"date-time":"2025-08-03T15:03:47Z","timestamp":1754233427000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/11\/3262"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,31]]},"references-count":64,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["jcm13113262"],"URL":"https:\/\/doi.org\/10.3390\/jcm13113262","relation":{"retraction":[{"id-type":"doi","id":"10.3390\/jcm13216388","asserted-by":"object"}]},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,31]]}}}